[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367733-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367733-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-screening-in-patients-with-acromegaly-a-plea-for-a-personalized-approach-and-international-registries","Cancer screening in patients with acromegaly - a plea for a personalized approach and international registries","","Acromegaly is a rare endocrine disorder often diagnosed years after onset, commonly leading to long-term respiratory, cardiovascular, and metabolic comorbidities that influence survival. Over recent decades, improved multidisciplinary care and new therapies reduced biochemically active disease, shifting leading mortality causes toward cancer. Neoplasms such as colon, thyroid, breast, prostate, and stomach are receiving greater attention. Chronic elevated growth hormone may contribute to cancer occurrence and progression, but consensus on screening methods and timing remains unclear, and risk factor data are insufficient. International/national registries are proposed to define risks and guide diagnostic and therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-screening-in-patients-with-acromegaly-a-plea-for-a-personalized-approach-and-international-registries/367733/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-screening-in-patients-with-acromegaly-a-plea-for-a-personalized-approach-and-international-registries/367733.png","ImageObject",300,407,{"name":42,"@type":43},"supergirl","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is cancer screening important in patients with acromegaly?","Question",{"text":63,"@type":64},"Cancer-related mortality has become more prominent as cardiovascular causes decrease with improved management. As neoplasms are increasingly observed, screening gains importance for comprehensive care.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What factors may contribute to increased cancer risk in acromegaly?",{"text":68,"@type":64},"Chronic exposure to elevated growth hormone and related IGF-1 signaling may promote tumorigenic processes, including increased proliferation and activation of pathways such as STAT5, MAPK, and PI3K/AKT.",{"name":70,"@type":61,"acceptedAnswer":71},"What gap exists regarding screening practices for acromegaly-associated cancer?",{"text":72,"@type":64},"No clear medical or societal agreement exists on screening methods or timing for neoplasm diagnosis in patients with acromegaly, and independent/dependent risk factor data remain lacking.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367733,1792180210,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962088121634,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries  \nLuigi Demarchis1,2 · Sabrina Chiloiro1,2 · Antonella Giampietro1,2 · Laura De Marinis1,2 · Antonio Bianchi1,2 · Maria Fleseriu3 · Alfredo Pontecorvi1,2  \nAccepted: 25 February 2025 / Published online: 15 March 2025 © The Author(s) 2025  \nAbstract  \nAcromegaly is a rare condition, and often diagnosis is delayed by several years, for most patients. Acromegaly is characterized by short and long-term respiratory, cardiovascular and metabolic comorbidities, with possible impact on mortality. In the last two decades, life expectancy has progressively increased in part due to a reduction in biochemically active disease, multidisciplinary treatment approaches and a reduction in complications, and the availability of new drugs. Of note, a leading cause of mortality, cardiovascular comorbidity, has been replaced by cancer(s). As such, neoplasms more frequently observed (colon, thyroid, breast, prostate, and stomach) in patients with acromegaly are receiving increased attention. Chronic exposure to increased growth hormone serum levels may contribute to an increase in the occurrence and progression of cancers. Various efforts have been made to determine the pathogenetic mechanisms involved. However, there are no clear medicalrelated societal agreement(s) in relation to screening methods or timing regarding neoplasm(s) diagnosis in patients with acromegaly. Additionally, independent and dependent risk factor data in patients with acromegaly is lacking. International/ national registries could help lay the groundwork to better study the impact of cancer(s) in patients with acromegaly and subsequently lead to and validate the most appropriate diagnostic and therapeutic path forward.  \nKeywords Somatotropinomas · Neoplasms · Screening · Colon · Breast · Prostate · Thyroid  \nAbbreviations  \nACG  \nAKT  \nATA  \nBSG  \nECIBC  \nEUSOBI  \nFNA  \nGal-3  \nAcromegaly Consensus Group  \nProtein kinase-B  \nAmerican Thyroid Association  \nBritish Society of Gastroenterology European Commission Initiative on Breast Cancer  \nEuropean Society of Breast Imaging Fine-needle aspiration  \nGalectine-3  \n* Sabrina Chiloiro [sabrina.chiloiro@unicatt.it](sabrina.chiloiro@unicatt.it)  \n1 Dipartimento Di Medicina Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy  \n2 Dipartimento Di Medicina Interna, Endocrinologia E Diabetologia, Fondazione Policlinico Universitario  \nA. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy  \n3 Pituitary Center, and Departments of Medicine, and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA  \nGH Growth hormone  \nIGF-1 Insulin growth hormone-1  \nIPSS International Prostatic Symptoms Score  \nMAPK Mitogen-activated protein kinase  \nNHSBSP National Health Service Breast Screening Program  \nPI3K Phosphatidylinositol 3-kinase  \nPSA Prostate-specific antigen  \nSMR Standard mortality ratio  \nSTAT5 Signal transducer and activator of transcription 5  \n1 Background  \nAcromegaly is a systemic disease, caused by the excessive secretion of the growth hormone (GH), due in most cases to the presence of a GH-secreting pituitary adenoma [1] . Overall, acromegaly is a rare disease, with a slightly increased prevalence and incidence over time [2] . While, in all countries, epidemiology is not well-defined disease  \nprevalence ranges from 28 to 137 cases per million with an incidence of 2–11 cases per million/year [3–7] .  \nThe mortality rate in patients with acromegaly is increased in those who have active disease, as compared to those who are living with controlled acromegaly and the general population. Standardized mortality ratio (SMR) is reportedly 0.98 (studies that enrolled patients on adjuvant treatment with somatostatin receptor ligands; SRLs) and 2.11 (studies with patients undergoing only surgery and/ or radiation therapy) [8] .  \nAcromegaly-related mortality is directly correlated wi","cbCaicPa8iDQjBbO","https://ap.wps.com/l/cbCaicPa8iDQjBbO","pdf",993705,14,"English","# Abstract\n# Keywords\n# Abbreviations\n# Background\n## Epidemiology and mortality\n## Treatment goals and remission\n## Biological mechanisms and cancer risk\n## Screening gaps and need for registries","[{\"question\":\"Why is cancer screening important in patients with acromegaly?\",\"answer\":\"Cancer-related mortality has become more prominent as cardiovascular causes decrease with improved management. As neoplasms are increasingly observed, screening gains importance for comprehensive care.\"},{\"question\":\"What factors may contribute to increased cancer risk in acromegaly?\",\"answer\":\"Chronic exposure to elevated growth hormone and related IGF-1 signaling may promote tumorigenic processes, including increased proliferation and activation of pathways such as STAT5, MAPK, and PI3K/AKT.\"},{\"question\":\"What gap exists regarding screening practices for acromegaly-associated cancer?\",\"answer\":\"No clear medical or societal agreement exists on screening methods or timing for neoplasm diagnosis in patients with acromegaly, and independent/dependent risk factor data remain lacking.\"}]","Cancer screening in patients with acromegaly - a plea for a personalized approach and international registries | PDF",1790172305,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/63148517df4669705736fa1e87e4fbd4.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/52d9aabc275d75640f6569ed3f1312f0.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/921b8a7e8bb42af17a4fd8f2b6b0021c.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/208a9c44c2726b60c46ce99343e51401.webp",980,1301]